Sarepta Therapeutics (SRPT) soars 114% premarket after the company announces its eteplirsen...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Sarepta Therapeutics (SRPT) soars 114% premarket after the company announces its eteplirsen treatment for Duchenne muscular dystrophy met its primary endpoint in a Phase IIb study. (PR)